

Ege Üniversitesi Tıp Fakültesi Tıbbi Onkoloji Kliniği Makale Saati Programı 2023-2024

Tarih	Konu	Sunan Hekim
04.10.23	<p>First-Line Nivolumab Plus Ipilimumab With Chemotherapy Versus Chemotherapy Alone for Metastatic NSCLC in CheckMate 9LA: 3-Year Clinical Update and Outcomes in Patients With Brain Metastases or Select Somatic Mutations</p> <p><u>Adding Nivolumab to Stereotactic Ablative Radiotherapy Might Extend Survival for Patients with Early-Stage NSCLC,</u></p>	Dr. Saadet Sim
18.10.23	<p>Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial</p> <p>Niraparib Plus Abiraterone Acetate and Prednisone Improves rPFS and Other Clinically Relevant Outcomes in First-Line Treatment for Patients with mCRPC(MAGNITUDE trial)</p>	Dr. Aslı Geçgel
01.11.23	<p><u>First-line systemic treatment strategies in patients with initially unresectable colorectal cancer liver metastases (CAIRO5): an open-label, multicentre, randomised, controlled, phase 3 study from the Dutch Colorectal Cancer Group</u></p> <p>Avelumab vs Standard Second-Line Chemotherapy in Patients With Metastatic Colorectal Cancer and Microsatellite Instability A Randomized Clinical Trial</p>	Dr. Caner Acar
15.11.23	<p><u>First-line cemiplimab monotherapy and continued cemiplimab beyond progression plus chemotherapy for advanced non-small-cell lung cancer with PD-L1 50% or more (EMPOWER-Lung 1): 35-month follow-up from a multicentre, open-label, randomised, phase 3 trial</u></p> <p>Tagrisso plus chemotherapy extended median progression-free survival by nearly 9 months in EGFR-mutated advanced lung cancer in FLAURA2 Phase III trial</p>	Dr. Salih Tünbekici

Ege Üniversitesi Tıp Fakültesi Tıbbi Onkoloji Kliniği Makale Saati Programı 2023-2024

29.11.23	<p>Perioperative Chemoimmunotherapy With Durvalumab for Muscle-Invasive Urothelial Carcinoma: Primary Analysis of the Single-Arm Phase II Trial SAKK 06/17</p> <p>Study EV-103: Neoadjuvant treatment with enfortumab vedotin monotherapy in cisplatin-ineligible patients (pts) with muscle invasive bladder cancer (MIBC): Updated results for Cohort H.</p>	Dr. Oğuzcan Özkan
13.12.23	<p>Neoadjuvant palbociclib plus either giredestrant or anastrozole in oestrogen receptor-positive, HER2-negative, early breast cancer (coopERA Breast Cancer): an open-label, randomised, controlled, phase 2 study</p> <p>Pertuzumab Plus Trastuzumab With or Without Chemotherapy Followed by Emtansine in <i>ERBB2</i>-Positive Metastatic Breast CancerA Secondary Analysis of a Randomized Clinical Trial</p>	Dr. Gökhan Şahin
27.12.23	<p>Efficacy of Metronomic Oral Vinorelbine, Cyclophosphamide, and Capecitabine vs Weekly Intravenous Paclitaxel in Patients With Estrogen Receptor-Positive, <i>ERBB2</i>-Negative Metastatic Breast CancerFinal Results From the Phase 2 METEORA-II Randomized Clinical Trial</p> <p>Capivasertib in Hormone Receptor-Positive Advanced Breast Cancer</p>	Dr Buket Şahin Çelik
08.11.23	<p>Final 5-Year Follow-Up Results Evaluating Neoadjuvant Talimogene Laherparepvec Plus Surgery in Advanced MelanomaA Randomized Clinical Trial</p> <p>Nivolumab Plus Ipilimumab vs Nivolumab Alone in Advanced Cancers Other Than MelanomaA Meta-Analysis</p>	Dr Haydar Çağatay Yüksel

<p>22.11.23</p>	<p><u>Cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy in patients with advanced ovarian cancer (OVHIPEC-1): final survival analysis of a randomised, controlled, phase 3 trial</u></p> <p>Intraperitoneal Carboplatin for Ovarian Cancer — A Phase 2/3 Trial</p>	<p>Dr. Fatma Pınar Açar</p>
<p>06.12.23</p>	<p>Olaparib plus abiraterone versus placebo plus abiraterone in metastatic castration-resistant prostate cancer (PROpel): final prespecified overall survival results of a randomised, double-blind, phase 3 trial</p> <p>Rucaparib or Physician’s Choice in Metastatic Prostate Cancer</p>	<p>Dr. Pınar Peker</p>
<p>Gelecek makaleler;</p>	<p>Preoperative Treatment of Locally Advanced Rectal Cancer(PROSPER trial)</p>	
	<p>Oral Selinexor as Maintenance Therapy After First-Line Chemotherapy for Advanced or Recurrent Endometrial Cancer</p>	
	<p>First-Line Enfortumab Vedotin Plus Pembrolizumab in Cisplatin-Ineligible Patients With Locally Advanced or Metastatic Urothelial Cancer</p>	
	<p>Perioperative Use of Pembrolizumab in Early-Stage NSCLC KEYNOTE 671</p>	
	<p><u>Tumor Treating Fields therapy with standard systemic therapy versus standard systemic therapy alone in metastatic non-small-cell lung cancer following progression on or after</u></p>	

Ege Üniversitesi Tıp Fakültesi Tıbbi Onkoloji Kliniği Makale Saati Programı 2023-2024

	<u>platinum-based therapy (LUNAR): a randomised, open-label, pivotal phase 3 study</u>	
	Preoperative Treatment of Locally Advanced Rectal Cancer(PROSPECT trial)	